Skip to main content
Support: 1-888-506-6887
Items in Cart (
0
)
[X]
Quick Order
Account
COVID-19 Research Tools
Antibodies
Primary Antibodies
Conjugated Antibodies
Sample Size Antibodies
KO Validated Antibodies
Recombinant Antibodies
Antibody Sampler Packs
Antibody Pairs
Secondary Antibodies
Isotype Control Antibodies
Proteins and Peptides
Peptides & Proteins
Blocking Peptides
Biologically Active Proteins
Lysates and Cell Lines
Lysates
Stem Cell Lines
Kits
Antibody Labeling Kits
ChIP Kits
ELISA Kits
Flow Cytometry Kits
Activators and Inhibitors
Inhibitors
Activators
Support Products
Exosome Isolation
Flow Cytometry Beads
IHC Tissue Slides
IHC Microarrays
Western Blot Gels & Buffers
Western Blot Membranes
All Support Products
Bulk and Custom
Products
Our Protocols
Resources
Protocols
Video Protocols
Troubleshooting Guides
Posters and Literature
Handbooks and Guides
Calculators
FAQs
Blogs
Diseases
Whitepapers
Webinars
Tools
Spectra Viewer
Flow Cytometry Panel Builder
Application
ELISA
Flow Cytometry
Mass Cytometry (CyTOF)
ICC
IHC
Western Blotting
Interviews
Faculty
Postdoc
Resources
View Pathways
By Research Area
Apoptosis
Autophagy
Cancer
Cell Biology
Cellular Markers
Epigenetics
Epitope Tags
Exosomes Research
Hypoxia
Immunology
Microbiology
Neuroscience
Stem Cells
By Pathway
AKT
Apoptosis
Autophagy
ERK1/2/5 Pathway
Hedgehog
Hippo
JNK Pathway
mTOR
Necroptosis
NFKB Signaling
p38 Signaling
TGF Beta
TLR
Research Areas
Get Rewards
Customer Care
100% Guarantee
Risk Free Testing
Novus Rewards Program
Publication Rewards Program
Scholarship
Travel Grants
Promotions
Customer Care
Novus Careers
About us
Careers
Collaborations
Events
Novus Story
Our Team
Philanthropy
Press Releases
Why choose Novus
About Us
Contact Us
Customer Service
Distributors
Technical Support
Contact
Home
» Siglec-3/CD33
Siglec-3/CD33
Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy
By Victoria Osinski, PhD
Tags:
Natural Killer Cell
NK Cell
Cancer
immunology
Immuno-oncology
Immunotherapy
CD8
MHC Class I
NKG2A/CD159a/KLRC1
NKG2C/CD159c/KLRC2
NKG2D/CD314
NKG2E/KLRC3
KLRC4
NKG2H
DAP12
Killer Cell Immunoglobulin-like Receptor
CD7
CD19
Siglec-3/CD33
MUC1
ErbB2/Her2
MICA
MICB
ULBP
HDAC
HLA G
KIR2DL4/CD158d
Victoria Osinski
Read more
about Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy
Log in
or
register
to post comments
Need help?
×
How can we help you?
Close
Start Chat
